Skip to main content

Volume 3 Supplement 1


Predictors of poor outcomes in critically ill patients with hematologic malignancy


Patients with hematologic malignancy (HM) often require admission to the intensive care unit (ICU) due to organ failure through disease progression or complications of treatment. Although there have been improvements in the prognosis of patients with HM, mortality in this patient population remains high. We sought to describe patient characteristics and determinants of outcomes in a Canadian tertiary care setting.


To identify prognostic variables and outcomes in patients with HM who are admitted to the ICU.


We performed a structured chart review of all adult patients (age > 18 years) with HM who were admitted to the ICU of a Canadian tertiary care hospital between 2004 and 2014. Outcome measures included ICU length of stay, prolonged ICU stay (> 10 days), ICU readmission, and mortality (ICU, 30-day, 60-day, and 12-month). A logistic regression model was adjusted for potential confounding variables and fitted to determine factors that were predictive of ICU readmission, prolonged ICU stay, and mortality.


Overall, 206 patients (mean age 51.3 ± 13.6 years; 60% male) with HM were admitted to the ICU during the study period. The most common types of HM were acute leukemia (34.5%) and lymphoma (33.5%). Less than half (44.7%) of patients had a stem cell transplant prior to admission. The most frequent ICU admission diagnosis was respiratory failure (39.8%), followed by hemodynamic instability (37.9%). The mean ICU stay was 3 ± 6 days, with 14.1% of patients requiring prolonged ICU stay. Readmission to the ICU was necessary for 13.1% of patients. During their ICU course, 71.8% of patients required mechanical ventilation and 56.8% required vasopressor therapy.

Of patients admitted to the ICU, 45.6% died during ICU admission, 30-day mortality was 59.2%, 60-day mortality was 62.6%, and 12-month mortality was 74.3%. After adjustment, factors predictive of mortality in the ICU were the need for mechanical ventilation (adjusted estimate [AE] 3.38; 95% CI 1.37, 8.37; P = 0.008) and need for vasopressor therapy (AE 3.65; 95% CI 1.67, 7.96; P = 0.001). A surgical procedure was associated with increased survival (AE 0.21; 95% CI 0.05, 0.86; P = 0.031). For mortality in survivors of ICU admission, myeloma was the only significant predictor of 30-day mortality (AE 0.21; 95% CI 0.06, 0.7; P = 0.011), 60-day mortality (AE 0.15; 95% CI 0.04, 0.52; P = 0.003), or 12-month mortality (AE 0.15; 95% CI 0.04, 0.52; P = 0.003).


Over a 10-year period, ICU mortality in patients with HM was 45.6% and 12-month mortality was 74.3%. Necessity for mechanical ventilation and vasopressor therapy were significant predictors of mortality in the ICU, while myeloma was predictive of longer term mortality.

Grant Acknowledgment

This study was funded by a Clinician Scientist Award from the Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cornish, M., Butler, M., Erdogan, M. et al. Predictors of poor outcomes in critically ill patients with hematologic malignancy. ICMx 3 (Suppl 1), A159 (2015).

Download citation

  • Published:

  • DOI: